Introduction
Deep venous thrombosis (DVT) is a common disorder with potential complications including pulmonary embolism and postthrombotic syndrome [1] . Compression ultrasonography (US) is widely used to establish a DVT diagnosis, with a sensitivity and specificity of 95% and 98%, respectively, for the detection of proximal leg veins thrombi [2] . However, another important issue is the therapeutic strategy, which highly depends on the thrombi age, acute thrombi being initially treated with anticoagulant, whereas chronic thrombi may need no therapy [3, 4] . It is a widespread approach to use the onset of symptoms for defining DVT age [3] [4] [5] [6] . Surprisingly, most patients who develop a DVT are asymptomatic [7] . Thus, it is important for the clinician to know the DVT age. Although US parameters (vein diameter and echogenicity of thrombi) are helpful for staging DVT, the optimal diagnostic threshold is still controversial due to wide disparity in different studies [6, 8, 9] . Additionally, it is also challenging to stage thrombi with other imaging modalities such as magnetic resonance (MR), computed tomography (CT), and nuclear techniques [10] [11] [12] [13] [14] .
thrombi harden as they age [16] [17] [18] , the hardening process is largely due to multiple factors, including organization of the thrombi and the clot transformation from one composed mainly of platelets to one composed mainly of fibrin. However, these studies were based on either animal or experimental models and had analyzed the evolution of thrombi elasticity only in acute stages. Few studies have evaluated US elasticity imaging of thrombi in humans [6, 19] . Moreover, all the thrombi elasticity results of these studies were not based on 2D-SWE [6, [16] [17] [18] [19] . A recent study used 2D-SWE to evaluate the elasticity of venous thrombi [20] , however, the results were also based on animal model.
To date, no study has reported the elasticity features of 2D-SWE in different stages of the common femoral vein thrombosis (CFVT) in humans. The purpose of this study was to evaluate whether adding 2D-SWE to US could improve the performance for staging CFVT.
Materials and methods

Patients
This prospective study was approved by the Institutional Review Board, and informed consent was obtained from all the subjects. Between January 2014 and July 2015, 289 consecutive patients (131 male, 158 female; mean age of 48.9±13.2 years, range of 17-94 years) with CFVT diagnosed by compression US were enrolled. The indications for vein US were as follows: a) swelling of lower limb; b) risk factors for DVT such as trauma, cancer, prolonged immobility, and oral contraceptive therapy; c) CFVT detected via US at a secondary or junior clinic; and d) follow-up examination of an existing CFVT, previously diagnosed by US. Of these, 95 patients were excluded for the following reasons: a) bilateral CFVT (n=11 ); b) CFVT thickness less than 2.0 mm (n=25 ) because the minimal region of interest (ROI) of 2D-SWE was of 2.0 mm; c) inconclusive evidence of CFVT duration due to either uncertain onset date of symptoms (n=13) or asymptomatic presentation (n=10); d) suspicion of recurrent CFVT (n=7) such as new symptoms of acute DVT or enlargement of thrombi thickness (≥2 mm) compared with those available from the previous US examination [21] ; e) prior thrombolytic treatment (n=13); and f) failure of either US (n=0) or 2D-SWE (n=16) acquisition. Ultimately, 194 patients (105 women and 89 men; 48.8±16.9 years; range 19-94 years) were enrolled in the final analysis. The CFVT age was defined as the duration from the onset of symptoms to presentation, either directly from examination or from the previous CFVT US examinations. These patients enrolled were categorized into three groups according to Conventional US and 2D-SWE imaging All US and 2D-SWE were performed using the same US machine (SuperSonic Imagine, Aix-en-Provence, France) with a 15-4 MHz linear probe by the same operator (F.S.P., with 5 years of experience in vascular US and 3 years of experience in US elastography) who was blinded to participant history. For each patient, all the US and 2D-SWE were performed on the same day. The US and 2D-SWE images of the targeted CFVT were obtained near the greater saphenous vein junction if thrombi were present at this level; otherwise, acquisitions were obtained at the most proximal level in the CFV containing clot.
To confirm the diagnosis of DVT and the extent of thrombi, the compression US was performed from the level of the common iliac vein to the calf veins in both transverse and longitudinal planes, including the femoral vein, the popliteal vein, and the great saphenous veins. Color and spectral Doppler US were applied to confirm whether obvious blood flow surrounding thrombi was detectable. All the grayscale US settings were standardized as follows: dynamic range 50, gain 40%, time gain compensation curve positioned at the center, and focus position at the bottom of CFV.
The 2D-SWE of CFVT was subsequently performed in the same longitudinal plane as US. The 2D-SWE settings were standardized as follows: gain 70%, option penetration, elasticity range 100 kPa, and smallest size of the color box, both 1.1 cm in width and length. When 2D-SWE mode was activated, the transducer was held steady with no movement or compression and the 2D-SWE box was moved to target the CFVT. The image was frozen and saved after a few seconds of immobilization. 2D-SWE acquisition was considered to be a failure when the signal was obtained in less than half of the 2D-SWE box. Three valid and consecutive 2D-SWE images were acquired in the same imaging plane for each patient.
Image interpretation All the images were digitally stored on the US system for subsequent offline analysis. One blinded radiologist (W.S.T.) with 2 years of experience in 2D-SWE reviewed the US and 2D-SWE features. Identification of the patients and clinical results were not available to the investigator.
The targeted CFVT was evaluated for occlusion degree (totally or partially occluded), depth (vertical dis-tance from the skin to the anterior wall of CFV), and CFVD_ratio (CFV diameter ratio of thrombosed leg to contralateral leg). Measurements of thrombosed CFV diameter were made by the use of transverse plane of CFV near the greater saphenous vein junction if thrombi were present at this level; otherwise, measurements were obtained at the most proximal level in the CFV containing clot. Measurements of the contralateral CFV diameter were obtained at the level similar to thrombosed CFV. Additionally, CFVT_echo (echo of CFVT) and Echo_ra-tio (echo ratio of CFVT to fat tissue) were quantitatively evaluated using Image J software (version 1.44p; National Institutes of Health, Bethesda, MD). A ROI with the size and shape fitted to the thrombi was manually drawn and the quantitative echogenicity of thrombi was obtained. Another ROI, with a circular shape of a diameter of 5 mm, was positioned at the layer of the fat tissue to obtain the corresponding echo value.
The size and the location of the ROI for 2D-SWE was standardized as follows: 1) the vessel wall and the obvious blood flow surrounding thrombi were avoided; 2) a proximal floating thrombus tip located at CFV was avoided; and 3) the number and site of ROIs for each image varied depending on the size of the thrombi. If two or more ROIs were applied, they should be placed without overlap. Thus, the number of ROIs for each image ranged from one to five because the width of 2D-SWE color box was of 1.1cm (fig 1-3) . The average spatial mean-value of all the ROIs measurements was used as the representative value of the CFVT for each acquisition. The average value of the three consecutive acquisitions was calculated as the ultimate elastic modulus of CFVT (CFVT_E).
Statistical analysis
Statistical analysis was performed using MedCalc Software, version 11.2 (MedCalc program, Belgium). The one-sample Kolmogorov-Smirnov test was used to test the normal distribution of the quantitative variables. When the quantitative variables were normally distributed, the results were described as mean values and standard deviations; otherwise, medians and interquartile ranges (IQR; 25 th -75th percentile) were reported. The qualitative variables were summarized as counts and percentages. Comparisons of clinical as well as US characteristics of the three groups were performed using either X 2 test or Fisher's exact test for categorical variables and ordinary two-way ANOVA analysis of variance by ranks for continuous variables. Spearman's coefficient was used to test the correlation between the CFVT stage and assay results. The diagnostic performance of US and 2D-SWE, as well as their combinations was assessed using receiver operating characteristic (ROC) curves and the area under the ROC curves (AUCs) using the following parameters: Stage A versus Stage B-C (=Stage A), and Stage A-B versus Stage C (=Stage C). The AUCs were compared by using the method proposed by DeLong et al [22] .The ROC curve analyses were also used to determine the optimal diagnostic cut-off value for US and 2D-SWE parameters, and the corresponding sensitivity and specificity were calculated, which were compared using the McNemar test. Both point estimates and 95% confidence intervals (CIs) were used. Statistical significance was defined as p<0.05 for two-tailed tests.
Results
Basic characteristics
The success rate of 2D-SWE was 92.4% (194 of 210). The reasons for 2D-SWE failure were as follows: acoustic shadowing due to scarring from either CFV drug injection (n=1) or previous inguinal surgical intervention (n=2), large CFVT depth due to obesity (n=10, body mass index (BMI) >32 kg/m 2 for all), inguinal hematoma (n=2) or femoral artery pseudoaneurysm (n=1). Among the 194 patients, thrombi were detected in the iliac vein of 122 patients, in the superficial femoral vein of 155 patients, in the popliteal vein of 104 patients and in the calf vein of 113 patients. There was no difference between the groups in regard to age, gender distribution, BMI, the percentage of left side CFVT and CFVT depth, except the percentage of CFV completely occluded by thrombi and patients receiving anticoagulation treatment (Table I) . 
Conventional US and 2D-SWE features
The US and 2D-SWE characteristics of the study patients are presented in Table II (fig 4) .
Diagnostic performance of conventional US and quantitative 2D-SWE features
The diagnostic performance of US and 2D-SWE features in predicting CFVT stages are detailed in Table III AUCs of CFVD_ratio were higher compared to CFVT_echo and Echo_ratio (p<0.01 for both), but no significant difference was observed compared to CFVT_E (p=0.630). For predicting Stage C, the AUCs of CFVD_ratio were the highest compared to CFVT_echo, Echo_ratio, and CFVT_E (p< 0.01 for all). However, contrary cutoff values were obtained for CFVT_echo and Echo_ratio.
Diagnostic performances of combined conventional US and 2D-SWE features
Due to contrary cutoff values for CFVT_echo and Echo_ratio in predicting Stage A and Stage C, both parameters cannot be regarded as a useful indicator for staging CFVT; thus we combined CFVD_ratio and CFVT_E to assess the diagnostic performance for staging CFVT (Table IV) . The AUCs were of 0.81 in predicting Stage A and of 0.67 in predicting Stage C, these values showed lower performance compared to CFVD_ ratio alone (p=0.0208 for Stage A, and p<0.0001 for Stage C). Meanwhile, this combination did not increase the specificity significantly (from 77.8% to 85.5%, p=0.216) and decreased the sensitivity (from 77.9% to 49.4%, p< 0.0001) for predicting Stage C. However, this combination increased the specificity from 80.3% to 92.7% (p<0.0001) without a significant reduction of sensitivity (from 77.2% to 70.2%, p=0.371) for predicting Stage A. CI -confidential interval. *Only AUCs were compared. The first column P value was compared to CFVD_ratio; the second column P value was compared to CFVT_echo; the third column P value was compared to Echo_ratio; the fourth column P value was compared to CFVT_E.
Discussions
According to the American College of Chest Physician (ACCP) guidelines, for patients diagnosed with acute iliofemoral DVTs with symptoms of less than 14 days, thrombolysis is specifically recommended instead of simple anticoagulation; duration of anticoagulant therapy may be of 3-6 months, or indefinite, depending on the risk factors of DVT [3] . In the present study we chose a 14 day period to define Stage A, also named as acute thrombi, and a cut-off of 6 month period to differentiate between Stages B and C. However, most patients who develop DVT are asymptomatic [7] . With the broad application of US, we believe that the frequency of detecting asymptomatic CFVT may be increasing. Thus, it is important for the clinician to know the CFVT age, especially whether it exceeds 14 days.
Fowlkes et al [9] reported that thrombi echogenicity is a useful feature for staging thrombi. However, their study was based on an experimental model, and the analysis time point was less than 14 days after thrombi initiation. Rubin et al [6] assessed the relative thrombi echogenicity of acute (<14 days) and chronic (>8 months) DVTs and revealed echogenicity difference between the two groups was highly significant, with AUC of 0.92. Conversely, Murphy et al [8] performed serial US follow-ups up to 6 months after the initial DVT diagnosis and semi-quantitatively analyzed the echogenicity in different patients. Their findings suggested that echogenicity is not reliable for staging thrombi. Several reasons might explain the inconsistent results of different studies. One reason might be the different enrollment criteria of thrombi age; another reason might be the system independent measurement of echogenicity which highly depends on the transducer frequency, thrombi depth, gain level of grayscale US, etc. In the present study, patients with CFVT were systematically enrolled in different stages, which ranged from 1 day to 288 months. Additionally, the grayscale US settings were standardized for all patients to eliminate measurement biases. We quantitatively analyzed CFVT_echo and Echo_ratio at different CFVT stages. Interestingly, contrary cutoff values were obtained for CFVT_echo (≤48. Murphy et al [8] also mentioned that venous diameter was useful in discriminating acute from chronic DVTs. However, they only evaluated diameter of thrombosed vein, contralateral vein diameter being ignored. That is, individual variations were not evaluated. Furthermore, the study did not obtain information regarding diagnostic performance. In the present study, we evaluated the CFVD ratio to eliminate individual variation and analyzed the performance in predicting CFVT stage. The AUCs were 0.87 for Stage A and 0.84 for Stage C, indicated that CFVD ratio was useful for distinguishing CFVT stage.
To date, this is the first study assessing CFVT elasticity in humans using 2D-SWE. Several studies [16] [17] [18] 20] based on experimental models reported that the elasticity of acute thrombi had increased gradually over time. Another study [19] evaluated only two patients in different stages of CFVT. Rubin et al [6] also evaluated the thrombi elasticity and showed a high AUC of 0.97 to discriminate acute (<14 days) from chronic (>8 months) DVTs. Moreover, all the thrombi elasticity results of these studies were not based on 2D-SWE technique, except the study based on experimental models by Mfoumou et al [20] . In the present study, the AUCs were of 0.85 in predicting Stage A and of 0.76 in predicting Stage C, which were significantly lower than the previous study reported [6] . Patients with thrombi aged between 14 days and 8 months were outside the scope of their study, which might be an important explanation for the inconsistent results. Additionally, different measurement system of elasticity might be another reason.
Many studies have focused on other imaging modalities in attempting to stage thrombi. MR imaging may be helpful in distinguishing acute from chronic DVTs [10] [11] [12] ; however, these findings were either preliminary or non-specific. With the emergence of nuclear medicine, Brighton et al [13] explored that the uptake image of 99m Tc-rt-PA into the thrombi might have a potential role for staging thrombi. However, none of these nuclear techniques have been widely adopted into clinical prac- Se -Sensitivity, Sp -Specificity, PPV -positive predictive value, NPV -negative predictive value, Ac -Accuracy tice. Furthermore, it is difficult to differentiate acute from chronic DVTs via CT scans or venography [14, 23] . Thus, it is challenging to stage thrombi for various imaging modalities available.
In view of this situation, a test with high specificity for staging thrombi is more important for a clinician who has to make an urgent treatment decision. Because US and 2D-SWE can be implemented using the same machine, combining them could be regarded as a onestop examination, which would make the simultaneous diagnosis and staging of the thrombi possible. US and 2D-SWE should be the preferred modalities due to their low cost, performance, elimination of radiation, and availability on bed-side. However, early stage DVT has potential complications, including pulmonary embolism and postthrombotic syndrome, thus a decrease of sensitivity of a diagnostic method is also not acceptable. In this study, we attempted to combine CFVD ratio with 2D-SWE for staging CFVT. If both methods were concordant, the AUCs were of 0.81 in predicting Stage A and of 0.67 in predicting Stage C, which both showed lower performance compared to CFVD ratio alone. Meanwhile, this combination did not significantly increase the specificity and decreased the sensitivity for predicting Stage C. However, we obtained a higher specificity and no significant reduction of sensitivity for predicting Stage A. In other words, combining 2D-SWE with US did not improve the diagnostic performance for staging CFVT compared to US alone. However, it is highly specific for predicting CFVT stage A without loss of sensitivity.
This study had several limitations. First, placing of ROIs was dependent on B-mode ultrasound criteria and thus might had suffered in cases of low echo signal differences such as between hypoechoic thrombi and blood. This might have led to falsely low values of CFVT_E. Second, up to 70.1% (136/194) of this population received anticoagulation treatment; it was conceivable that untreated thrombi might have not behaved similarly to a treated thrombi. Third, owing to a relatively high probe used in our study, it limited the resolution on B-mode US as well as 2D-SWE. Thus, we only assessed patients with CFVT. Although studies have revealed that iliofemoral DVT was more common than calf DVT, and no pathological or structural differences were associated with thrombi location [5] , no generalizations could be made until DVTs involving other locations were studied. Fourth, this study was executed in our single institution; thus, our findings need to be validated in larger multicenter trial.
In conclusion, adding 2D-SWE to US did not improve the diagnostic performance for staging CFVT compared with US alone. However, it is highly specific for predicting Stage A (less than 14 days) without loss of sensitivity, suggesting that 2D-SWE may be a promising adjunctive tool for risk stratification and therapy planning.
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